Evidence map›Paper›PMID 40359056›Full record

ArticleJournal of the American Society of Nephrology : JASN2025

Safety and Efficacy of Vadadustat for the Treatment of CKD-Related Anemia within and outside the United States.

Glenn M Chertow, Kai-Uwe Eckardt, Mark J Sarnak, Wolfgang C Winkelmayer, Rajiv Agarwal, Todd Minga, Wenli Luo, Steven K Burke

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of the American Society of Nephrology : JASN, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Navigating Anemia Therapy in CKD With Hypoxia-Inducible Factor Activators: A Review.American journal of kidney diseases : the official journal of the National Kidney Foundation · 2026
    Review
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Glenn M ChertowDepartments of Medicine, Epidemiology and Population Health, and Health Policy, Stanford University School of Medicine, Stanford, California.ORCID 0000-0002-7599-0534
Kai-Uwe EckardtDepartments of Medicine, Epidemiology and Population Health, and Health Policy, Stanford University School of Medicine, Stanford, California.ORCID 0000-0003-3823-0920
Mark J SarnakDepartment of Medicine, Tufts Medical Center, Boston, Massachusetts.ORCID 0000-0003-1860-6302
Wolfgang C WinkelmayerDepartment of Medicine, Baylor College of Medicine, Houston, Texas.ORCID 0000-0002-5272-425
Rajiv AgarwalDepartment of Medicine, Richard L. Roudebush Veterans Administration Medical Center, Indiana University School of Medicine, Indianapolis, Indiana.ORCID 0000-0001-8355-7100
Todd MingaAkebia Therapeutics, Inc., Cambridge, Massachusetts.
Wenli LuoAkebia Therapeutics, Inc., Cambridge, Massachusetts.
Steven K BurkeAkebia Therapeutics, Inc., Cambridge, Massachusetts.ORCID 0000-0002-9073-0239

Funding

Akebia Therapeutics Not applicable
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

anemiacardiovascular eventsCKDclinical trialESKD

Identifiers

PMID40359056
PMCPMC12499611

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.